nach oben

Erschienen in:

10.07.2020 | Original Article

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

verfasst von: Eiki Ichihara, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Immune checkpoint inhibitors (ICIs) are less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, a small percentage of patients with EGFR-mutant NSCLC do respond, and the characteristics of these patients are not known. Here, we identify the characteristics of patients who may respond to ICI therapy for EGFR-mutant NSCLC.

Patients and methods

The medical records of NSCLC patients with EGFR mutations who received PD-1/PD-L1 antibody monotherapy at nine institutions were reviewed.

Results

In total, 58 patients with EGFR-mutant NSCLC were analyzed. Various clinical factors such as smoking history and EGFR mutation type were not associated with progression-free survival (PFS) of ICIs, while the PFS of prior EGFR tyrosine kinase inhibitors (TKIs) was inversely associated with that of ICIs. Patients who responded to prior EGFR TKIs for > 10 months exhibited a significantly shorter response to ICIs compared to those who had responded for ≤ 10 months (PFS of ICI: 1.6 vs. 1.9 months; hazard ratio: 2.54; 95% confidence interval 1.26–5.12; p = 0.009). However, patients who responded to ICIs for > 6 months responded to prior EGFR TKIs for significantly shorter periods compared to those who responded to ICIs for ≤ 6 months (PFS of prior EGFR TKI: 5.3 vs. 12.1 months; log-rank test: p = 0.0025).

Conclusion

The duration of response to prior EGFR TKIs could be a predictive marker of ICI therapy in EGFR-mutant NSCLC patients.

Nur mit Berechtigung zugänglich

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627CrossRefPubMedPubMedCentral

Reck M, Rodriguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37:537–546. https://doi.org/10.1200/JCO.18.00149CrossRefPubMed

Lee CK, Man J, Lord S et al (2018) Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol 4:210–216. https://doi.org/10.1001/jamaoncol.2017.4427CrossRefPubMed

Reck M, Mok TSK, Nishio M et al (2019) Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7:387–401. https://doi.org/10.1016/S2213-2600(19)30084-0CrossRefPubMed

Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M, Lee CK (2018) Defining the most appropriate primary end point in Phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis. JAMA Oncol 4:522–528. https://doi.org/10.1001/jamaoncol.2017.5236CrossRefPubMedPubMedCentral

Offin M, Rizvi H, Tenet M et al (2019) Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res 25:1063–1069. https://doi.org/10.1158/1078-0432.CCR-18-1102CrossRefPubMed

Hastings K, Yu H, Wei W et al (2019) EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Ann Oncol. https://doi.org/10.1093/annonc/mdz141CrossRefPubMedPubMedCentral

Yamada T, Hirai S, Katayama Y et al (2019) Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Med 8:1521–1529. https://doi.org/10.1002/cam4.2037CrossRefPubMedPubMedCentral

10.

Isomoto K, Haratani K, Hayashi H et al (2020) Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res 26:2037–2046. https://www.ncbi.nlm.nih.gov/pubmed/31937613

Titel: Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors
verfasst von: Eiki Ichihara
Daijiro Harada
Koji Inoue
Takuo Shibayama
Shinobu Hosokawa
Daizo Kishino
Shingo Harita
Nobuaki Ochi
Naohiro Oda
Naofumi Hara
Katsuyuki Hotta
Yoshinobu Maeda
Katsuyuki Kiura
Publikationsdatum: 10.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 1/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02662-0

Springer Medizin

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors